Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.

Jiménez-Triana CA, Castelán-Martínez OD, Rivas-Ruiz R, Jiménez-Méndez R, Medina A, Clark P, Rassekh R, Castañeda-Hernández G, Carleton B, Medeiros M; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Medicine (Baltimore). 2015 Aug;94(34):e1413. doi: 10.1097/MD.0000000000001413.

2.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.

3.

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium.

Pharmacogenomics. 2015;16(10):1065-76. doi: 10.2217/pgs.15.61. Epub 2015 Jul 31.

PMID:
26230641
4.

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.

Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC; CPNDS Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):142-9. doi: 10.1038/clpt.2013.55. Epub 2013 Mar 18.

5.

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR; CPNDS Consortium.

Clin Pharmacol Ther. 2013 Aug;94(2):243-51. doi: 10.1038/clpt.2013.80. Epub 2013 Apr 10.

6.

Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Pharmacogenomics J. 2014 Apr;14(2):160-70. doi: 10.1038/tpj.2013.13. Epub 2013 Apr 16.

7.

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium.

Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.

PMID:
23441093
8.

Audit of renal drug dosing: comparison of 2 methods and evaluation of pharmacists' knowledge, attitudes, and behaviour.

Caouette KL, Raymond CB, Meyer LD, Honcharik N.

Can J Hosp Pharm. 2012 Jul;65(4):277-84.

9.

Organizational restructuring of regional pharmacy services to enable a new pharmacy practice model.

Hall KW, Raymond CB, Woloschuk DM, Honcharik N.

Can J Hosp Pharm. 2011 Nov;64(6):451-6. No abstract available.

10.

Attitudes and behaviours of hospital pharmacy staff toward near misses.

Raymond CB, Woloschuk DM, Honcharik N.

Healthc Q. 2011;14(3):48-56.

PMID:
21841377
11.

Reliability and validity of a survey to evaluate attitudes and behaviours of pharmacy staff toward near misses.

Raymond CB, Miller SH, Wheaton HR, Honcharik N.

Healthc Manage Forum. 2010 Spring;23(1):32-7.

PMID:
20527317
12.

Impact of a target drug monitoring program on the usage of clindamycin.

Gin AS, Lipinski LA, Honcharik N.

Can J Hosp Pharm. 1994 Apr;47(2):53-8.

PMID:
10134127
13.

Eliminating needless testing in intensive care--an information-based team management approach.

Roberts DE, Bell DD, Ostryzniuk T, Dobson K, Oppenheimer L, Martens D, Honcharik N, Cramp H, Loewen E, Bodnar S, et al.

Crit Care Med. 1993 Oct;21(10):1452-8.

PMID:
8403952
14.

Distribution of cyclosporin G (NVa2 cyclosporin) in blood and plasma.

Yatscoff RW, Honcharik N, Lukowski M, Thliveris J, Chackowsky P, Faraci C.

Clin Chem. 1993 Feb;39(2):213-7.

15.

Pharmacokinetics of rapamycin: single-dose studies in the rabbit.

Honcharik N, Fryer J, Yatscoff R.

Ther Drug Monit. 1992 Dec;14(6):475-8.

PMID:
1485369
16.

The effect of meal composition on cyclosporine absorption.

Honcharik N, Yatscoff RW, Jeffery JR, Rush DN.

Transplantation. 1991 Dec;52(6):1087-9. No abstract available.

PMID:
1750071
17.

The effect of food on cyclosporine absorption.

Honcharik N.

Clin Biochem. 1991 Feb;24(1):89-92. Review.

PMID:
2060138
18.

Diltiazem overdose: pharmacokinetics of diltiazem and its metabolites and effect of multiple dose charcoal therapy.

Roberts D, Honcharik N, Sitar DS, Tenenbein M.

J Toxicol Clin Toxicol. 1991;29(1):45-52.

PMID:
2005665
19.

Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.

Copeland K, Lukowski M, Yatscoff R, Thliveris J, Honcharik N.

Drug Metab Dispos. 1990 Mar-Apr;18(2):226-30.

PMID:
1971578
20.

Systemic absorption of intraurethral lidocaine.

Yatscoff RW, Honcharik N, Tenenbein M.

CMAJ. 1987 Dec 1;137(11):992. No abstract available.

Supplemental Content

Loading ...
Support Center